← Back

Wire · opportunities

'Pan-RAS molecular glue' is a safe and effective treatment for lung and pancreatic cancers

Published

21 November 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at medicalxpress.com →

◆ Verified

Fusion42 · 21 November 2026 · Fusion42 review

The Phase I AURORAS-1 trial shows ERAS-0015, a pan-RAS molecular glue, is safe and effective in shrinking tumors in patients with RAS-mutant lung and pancreatic cancers, offering a promising treatment for previously hard-to-treat cases.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

Your biotech startup now faces a shift where targeting RAS mutations with molecular glues is viable, opening a path to develop drugs for cancers long viewed as untreatable. Accelerate work on RAS-related drug candidates or risk losing first-mover advantage in precision oncology.

◆ Coverage

1 source · 21 Nov 2026

◆ Related on Wire

◆ Topics

Biotechpan-rasmolecular-glueclinical-trialprecision-oncologylung-cancerpancreatic-cancer